<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of retroperitoneal fibrosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of retroperitoneal fibrosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of retroperitoneal fibrosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Augusto Vaglio, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alessandra Palmisano, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary C Curhan, MD, ScD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marcello Tonelli, MD, SM, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retroperitoneal fibrosis (RPF) is a rare condition characterized by the presence of inflammatory and fibrous tissue in the retroperitoneum. The tissue is generally localized around the infrarenal portion of the abdominal aorta and the iliac arteries, often encasing the ureters or other abdominal organs [
         <a href="#rid1">
          1
         </a>
         ]. This disorder was initially called Ormond's disease [
         <a href="#rid2">
          2
         </a>
         ] and has also been referred to as periureteritis fibrosa, periureteritis plastica, chronic periureteritis, and fibrous retroperitonitis.
        </p>
        <p>
         RPF may be primary (idiopathic) or secondary. Idiopathic disease accounts for 70 percent of cases and can be immunoglobulin G4 (IgG4)- or nonIgG4-related. It may develop alone or in association with other autoimmune entities, and it may involve other vascular districts (mainly the thoracic aorta and epiaortic vessels). Secondary RPF can result from infections, malignancy, drugs, retroperitoneal hemorrhage, or various other disorders.
        </p>
        <p>
         Idiopathic RPF, inflammatory abdominal aortic aneurysm, and perianeurysmal RPF are all forms of chronic periaortitis and are marked histologically by a mixture of fibrous tissue and chronic inflammation [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The epidemiology, pathogenesis, clinical features, and diagnostic evaluation of nonIgG4-related idiopathic RPF and secondary RPF will be reviewed here. The treatment of RPF is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7213.html" rel="external">
          "Treatment of retroperitoneal fibrosis"
         </a>
         .)
        </p>
        <p>
         Related diseases are presented elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IgG4-related disease including IgG4-related idiopathic RPF (see
         <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">
          "Clinical manifestations and diagnosis of IgG4-related disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121219.html" rel="external">
          "Treatment and prognosis of IgG4-related disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Castleman disease (see
         <a class="medical medical_review" href="/z/d/html/90340.html" rel="external">
          "Unicentric Castleman disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4707.html" rel="external">
          "HHV-8/KSHV-associated multicentric Castleman disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117312.html" rel="external">
          "HHV-8-negative/idiopathic multicentric Castleman disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erdheim-Chester disease (see
         <a class="medical medical_review" href="/z/d/html/13942.html" rel="external">
          "Erdheim-Chester disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H90857066">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         RPF is a rare disease, and few epidemiologic studies are available. In various studies, the incidence of idiopathic (primary) disease ranged from 0.1 to 1.3 cases per 100,000 persons per year [
         <a href="#rid4">
          4-6
         </a>
         ]. Inflammatory abdominal aortic aneurysm, a manifestation of RPF, accounts for 4 to 10 percent of all abdominal aortic aneurysms [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Idiopathic disease is most prevalent in individuals 40 to 60 years of age [
         <a href="#rid5">
          5,8-10
         </a>
         ]. Some [
         <a href="#rid5">
          5,8-10
         </a>
         ] but not all [
         <a href="#rid11">
          11,12
         </a>
         ] studies suggest a 2:1 to 3:1 male-to-female predominance. Exposure to either asbestos or tobacco smoke may result in a three- to fourfold increase in the risk of RPF [
         <a href="#rid13">
          13,14
         </a>
         ]. The combination of smoking and asbestos exposure is associated with an 8- to 12-fold increased risk [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         The incidence of secondary RPF is not known.
        </p>
        <p class="headingAnchor" id="H1085297711">
         <span class="h1">
          ETIOLOGY AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         RPF may be idiopathic or secondary to other causes. Idiopathic RPF is an immune-mediated disease accounting for over 70 percent of cases. It can either present in isolation or in association with other autoimmune diseases and/or inflammatory disorders, such as the fibroinflammatory immunoglobulin G4 (IgG4)-related disease [
         <a href="#rid15">
          15
         </a>
         ]. IgG4-related RPF accounts for 35 to 60 percent of idiopathic RPF [
         <a href="#rid16">
          16,17
         </a>
         ]. The pathogenesis of the IgG4-related disease is discussed at length elsewhere.
        </p>
        <p>
         Although there are no standardized criteria for classification, idiopathic RPF is part of the disease spectrum of chronic periaortitis (CP), a condition characterized by inflammation and fibrosis surrounding the aorta and iliac arteries [
         <a href="#rid1">
          1,11,18
         </a>
         ]. CP includes periaortic RPF (in which the aortic caliber is normal) and inflammatory abdominal aortic aneurysm (in which the aorta is dilated); these two entities are grouped together because of similar clinical and histologic characteristics [
         <a href="#rid10">
          10,19
         </a>
         ]. Most cases of idiopathic RPF are classifiable as CP because they have the typical peri-aortoiliac localization. Idiopathic RPF cases that cannot be classified as CP are those atypically localized (eg, pelvic, peri-pancreatic, isolated peri-ureteral).
        </p>
        <p>
         Idiopathic RPF (in its typical periaortic presentation) probably arises as an aortitis and elicits a periaortic fibroinflammatory response. This phenomenon can be a manifestation of a systemic autoimmune disease, a hypothesis that is supported by frequent presence of constitutional symptoms, elevated levels of acute phase reactants, presence of autoantibodies, a prompt response to glucocorticoids or other immunosuppressive drugs, and coexistence of autoimmune diseases involving other organs [
         <a href="#rid20">
          20
         </a>
         ]. In addition, the disease often involves other vascular segments such as the thoracic aorta and mesenteric arteries, suggesting a multifocal origin [
         <a href="#rid21">
          21
         </a>
         ]. This multifocal presentation is seen in idiopathic RPF (whether IgG4-related or not), but is usually not associated with secondary RPF due to malignancy, radiotherapy, or surgery.
        </p>
        <p>
         A multifactorial pathogenesis is likely, and environmental and genetic factors contribute to disease susceptibility. Among environmental factors, smoking and exposure to asbestos are major risk factors for idiopathic RPF. The main genetic associations are with HLA-DRB1*03, a genetic marker of autoimmunity [
         <a href="#rid22">
          22
         </a>
         ]. This genetic association suggests that the disease may be antigen driven. Antigen-presenting cells probably present antigens to cluster of differentiation 4 positive (CD4+) cells within the aortic wall and retroperitoneum. CD4+ T cells then expand and secrete interleukin (IL)-6, which is able to activate B cells and fibroblasts. CD4+ T cells also secrete Th2 cytokines, such as IL-4, IL-10, IL-13, and transforming growth factor beta (TGF-beta), which drive the proliferation and maturation of B cells into plasma cells, and thereby, may result in preferential expansion of IgG4-producing plasma cells [
         <a href="#rid23">
          23,24
         </a>
         ]. Local and systemic production of IL-6 and Th2 cytokines has been demonstrated in idiopathic RPF. A complex network of chemokines (eg, CXCL12 and CCL11) and cytokines (eg, IL-6, IL-12, and IL-13) likely mediates the inflammatory response and simultaneously promotes fibrosis [
         <a href="#rid25">
          25
         </a>
         ]. These findings are observed both in IgG4-related and unrelated forms of idiopathic RPF [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         Secondary RPF can be caused by a number of conditions [
         <a href="#rid1">
          1,4,8,13,18,28-31
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs – Ergot alkaloids (eg, methysergide,
         <a class="drug drug_general" data-topicid="9416" href="/z/d/drug information/9416.html" rel="external">
          ergotamine
         </a>
         ) and dopamine agonists (eg, pergolide,
         <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">
          methyldopa
         </a>
         ). The increased serotonin levels may lead to fibrotic reactions through proliferation of myofibroblasts and an increase in collagen matrix deposition.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biological agents such as
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , a soluble receptor that acts as a tumor necrosis factor (TNF)-alpha blocker, and
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         , an anti-TNF-alpha monoclonal antibody. These agents may trigger a fibrotic reaction but the mechanism is unknown.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancy – Carcinoid, Hodgkin and non-Hodgkin lymphoma, sarcomas, colorectal, breast, prostate, and bladder carcinoma may cause secondary RPF. In most cases, RPF is due to an exuberant desmoplastic response associated with retroperitoneal metastases or a primary tumor. However, with carcinoid tumors, fibrosis is mediated by the release of serotonin and other fibrogenic growth factors  (
         <a class="graphic graphic_diagnosticimage graphicRef93886" href="/z/d/graphic/93886.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef93885" href="/z/d/graphic/93885.html" rel="external">
          image 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infections –Spinal or paraspinal abscess, tuberculosis, histoplasmosis, and actinomycosis may lead to RPF; in these cases, the retroperitoneum may be the site of the primary infection or may be involved as a result of local spread.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation therapy for testicular seminoma, colon, or pancreatic cancer  (
         <a class="graphic graphic_diagnosticimage graphicRef93887" href="/z/d/graphic/93887.html" rel="external">
          image 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retroperitoneal hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgery – Lymphadenectomy, colectomy, aortic aneurysmectomy.
        </p>
        <p>
        </p>
        <p>
         In addition, there are case reports of RPF associated with secondary (AA) amyloidosis, mesenteric panniculitis, and different forms of histiocytosis, particularly Erdheim-Chester disease [
         <a href="#rid32">
          32-35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2602.html" rel="external">
          "Sclerosing mesenteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13942.html" rel="external">
          "Erdheim-Chester disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         RPF frequently presents with a nonspecific clinical pattern, and therefore diagnosis may be delayed. Most patients with RPF present with pain; estimated glomerular filtration rate (eGFR) is often decreased at the time of presentation.
        </p>
        <p>
         Pain in the lower back, abdomen, or flank is the most common presenting symptom among patients with RPF [
         <a href="#rid18">
          18
         </a>
         ]. In two of the largest retrospective series, pain was noted on presentation in over 90 percent of patients [
         <a href="#rid5">
          5,11
         </a>
         ]. Pain tends to be dull and poorly localized, is not affected by activity or posture, and can be characterized by nocturnal exacerbation. Some patients may describe unilateral or bilateral flank pain that radiates to the inguinal region [
         <a href="#rid11">
          11
         </a>
         ]. Testicular pain was noted in more than 50 percent of male patients in one study [
         <a href="#rid10">
          10
         </a>
         ]. Pain may be acute in onset and can be mistaken for renal colic. Pain may be more responsive to nonsteroidal antiinflammatory agents compared with opiates, probably due to the inflammatory nature of the lesion.
        </p>
        <p>
         Other common symptoms, which may occur with pain or in isolation, include malaise, anorexia, weight loss, fever, nausea, vomiting, and lower extremity edema [
         <a href="#rid5">
          5,11,36,37
         </a>
         ]. Edema may be due to inferior vena cava or lymphatic compression.
        </p>
        <p>
         Patients may complain of urinary frequency, urgency, and dysuria [
         <a href="#rid10">
          10
         </a>
         ]. Urine output may be reduced, normal, or even increased (due to a secondary concentrating defect) in patients with obstructive uropathy. Gross hematuria is uncommon.
        </p>
        <p>
         Less commonly, patients may present with claudication due to compromise of the arterial circulation of the lower extremities [
         <a href="#rid1">
          1,5
         </a>
         ] or abdominal pain due to mesenteric ischemia from compression of the mesenteric arteries [
         <a href="#rid1">
          1,9,18,38-40
         </a>
         ]. Compression of the thoracic aorta and/or the epi-aortic arteries can lead to hoarseness and dry cough secondary to recurrent laryngeal nerve paralysis, or upper-limb claudication [
         <a href="#rid1">
          1,5,12
         </a>
         ].
        </p>
        <p>
         On physical examination, new-onset hypertension (likely due to encasement of renal arteries producing renovascular hypertension) is noted in approximately 30 to 60 percent of patients [
         <a href="#rid5">
          5,9,11,18,38-40
         </a>
         ]. Patients may have lower extremity edema, thrombophlebitis, or deep vein thrombosis resulting from obstruction of the inferior vena cava and/or iliac veins. In most cases, compression of the venous axis is a gradual process that leads to the formation of collateral venous circulation [
         <a href="#rid41">
          41
         </a>
         ]. Hydrocele or varicocele, likely from compression of retroperitoneal testicular vessels, are common among men with RPF, seen in approximately 30 to 60 percent of patients [
         <a href="#rid5">
          5,10,11
         </a>
         ].
        </p>
        <p>
         Kidney function impairment with elevated blood urea nitrogen and creatinine, most commonly due to obstruction, is present in more than 50 percent of patients at presentation [
         <a href="#rid5">
          5,10
         </a>
         ]. Patients may also have normocytic anemia, even among those with preserved kidney function. (See
         <a class="local">
          'Laboratory studies'
         </a>
         below.)
        </p>
        <p>
         Prior to the diagnosis of RPF, patients may undergo a kidney ultrasound as part of their evaluation for kidney function impairment or acute flank pain. Kidney ultrasound may reveal hydronephrosis with or without bilateral encasement of renal vessels by peri-iliac fibrotic tissue [
         <a href="#rid1">
          1,5,12
         </a>
         ]. At diagnosis, 8 to 30 percent of patients may have unilateral or bilateral kidney parenchymal atrophy either from slowly progressive or intermittent ureteral obstruction, or from chronically diminished blood supply due to renal artery compression.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIAGNOSTIC APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H3302014059">
         <span class="h2">
          When to suspect the disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         RPF should be suspected among patients who have characteristic clinical features, such as flank or abdominal pain, in association with newly detected kidney function impairment. However, it is more commonly identified incidentally when radiologic studies are performed to evaluate for urinary tract obstruction or lower limb venous or arterial insufficiency.
        </p>
        <p>
         Patients with a suspected diagnosis of RPF should undergo further testing to confirm the diagnosis. (See
         <a class="local">
          'Diagnosis (contrast CT or MRI preferred)'
         </a>
         below and
         <a class="local">
          'Indications for a biopsy and diagnostic histopathology'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2234181835">
         <span class="h2">
          Diagnosis (contrast CT or MRI preferred)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of RPF is often made either by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI). However, findings on imaging are characteristic but not pathognomonic. Thus, the diagnosis integrates imaging and clinical presentation [
         <a href="#rid42">
          42
         </a>
         ]. A definitive diagnosis may require a biopsy in some patients. (See
         <a class="local">
          'Indications for a biopsy and diagnostic histopathology'
         </a>
         below.)
        </p>
        <p>
         In addition to revealing the presence of RPF, cross-sectional imaging of the chest, abdomen, and pelvis can sometimes suggest a secondary cause of RPF (eg, malignancy, prior surgery, prior radiotherapy). By contrast, other causes of secondary RPF may be radiographically indistinguishable from idiopathic RPF (eg, drug-induced RPF).
        </p>
        <p>
         A contrast-enhanced CT enables visualization of the extent of RPF  (
         <a class="graphic graphic_diagnosticimage graphicRef93889" href="/z/d/graphic/93889.html" rel="external">
          image 4
         </a>
         ) and the presence of lymphadenopathy or tumors [
         <a href="#rid43">
          43,44
         </a>
         ]. Typical findings of idiopathic RPF include presence of a confluent retroperitoneal mass, with homogeneous attenuation similar to muscle, that encases (but not displaces) the anterior and lateral sides of the aorta, encircles and compresses the inferior vena cava, and often causes a medial deviation of the ureters  (
         <a class="graphic graphic_diagnosticimage graphicRef55419" href="/z/d/graphic/55419.html" rel="external">
          image 5
         </a>
         ) [
         <a href="#rid45">
          45
         </a>
         ]. Localized reactive lymphadenopathy, generally with subcentimeter lymph nodes adjacent to the mass, is observed in approximately 25 percent of the cases [
         <a href="#rid5">
          5
         </a>
         ]. No infiltration of the muscle or the bone is seen. The fibroproliferative tissue of RPF can have varying degrees of contrast enhancement depending upon the extent of active inflammation [
         <a href="#rid46">
          46
         </a>
         ]. Assessment of renal vascular involvement (in the contrast-enhanced phase) is an important aspect of the evaluation [
         <a href="#rid11">
          11
         </a>
         ]. In addition to its diagnostic advantages, a CT also allows a CT-guided vascular interventional procedure or biopsy of the tissue, when indicated [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         MRI is equivalent to CT in the diagnosis of RPF [
         <a href="#rid48">
          48
         </a>
         ], but may be the preferred imaging modality among patients with an iodinated contrast allergy or significantly reduced estimated glomerular filtration rate at presentation. Compared with CT, MRI has better definition and a higher contrast resolution relative to surrounding tissues. The use of gadolinium is recommended in order to define the exact extension of the tissue and to study the vasculature; however, if gadolinium cannot be used, unenhanced MRI can still differentiate RPF from the surrounding tissues. On MRI, idiopathic RPF appears hypointense in T1-weighted images; in T2-weighted images, its intensity is low (with a characteristic delayed-phase enhancement) in the quiescent phases of the disease and high in the active stages, when there is abundant tissue edema and hypercellularity [
         <a href="#rid49">
          49
         </a>
         ]. MRI is also useful for the differential diagnosis since malignant lesions are more likely to have a bulky appearance, to be inhomogeneous, to originate above renal arteries, to cause anterior aorta displacement, and to produce lateral ureteral deviation  (
         <a class="graphic graphic_diagnosticimage graphicRef93893" href="/z/d/graphic/93893.html" rel="external">
          image 6
         </a>
         ) [
         <a href="#rid48">
          48-50
         </a>
         ]. In our experience, when patients present with suspected RPF that has characteristic MRI features, the diagnosis can be made without biopsy. A detailed discussion regarding risks and benefits of gadolinium use with MRI is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"
         </a>
         .)
        </p>
        <p>
         Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) is a useful and reliable technique to assess the metabolic or inflammatory activity of the disease [
         <a href="#rid51">
          51
         </a>
         ], but cannot be used to make a diagnosis of RPF.
        </p>
        <p>
         We do not use intravenous urography (also known as intravenous pyelography) or retrograde pyelography for diagnosis, but these procedures may be used for further evaluation and management of hydronephrosis at the discretion of urologists. (See
         <a class="medical medical_review" href="/z/d/html/7174.html" rel="external">
          "Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15182.html" rel="external">
          "Placement and management of indwelling ureteral stents"
         </a>
         .)
        </p>
        <p>
         Indications and details of additional imaging in patients suspected of having IgG4-related RPF is discussed at length elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">
          "Clinical manifestations and diagnosis of IgG4-related disease", section on 'Laboratory evaluation'
         </a>
         .) [
         <a href="#rid52">
          52,53
         </a>
         ]
        </p>
        <p class="headingAnchor" id="H3109066744">
         <span class="h2">
          Indications for a biopsy and diagnostic histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is controversial whether or not patients who have diagnostic features of idiopathic RPF by CT or MRI require a biopsy to confirm the diagnosis. The risk of complications resulting from biopsy (primarily bleeding) must be weighed against the benefits of having a histopathologic diagnosis.
        </p>
        <p>
         Many clinicians do not perform a biopsy in patients who have an imaging diagnosis of idiopathic RPF, unless the patient is about to undergo surgery for repair of abdominal aortic aneurysm (in the case of inflammatory aneurysms or perianeurysmal fibrosis) or for surgical ureterolysis to treat urinary tract obstruction [
         <a href="#rid1">
          1,18
         </a>
         ].
        </p>
        <p>
         We suggest a biopsy in the following settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the location of the mass is atypical (eg, not peri-aortoiliac but instead in a pelvic, isolated peri-ureteral, or peri-bladder location).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If clinical and laboratory findings suggest the presence of an underlying malignancy or infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there is bulky appearance of the retroperitoneal tissue, extension above the origin of the renal arteries, anterior displacement of the aorta, or infiltration of muscles, bone, or other structures and confluent lymphadenopathy. This appearance suggests the possibility of an underlying malignancy (eg, lymphoma, sarcoma, or other solid neoplasms).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there is a perirenal fibrotic tissue. This appearance suggests the possibility of underlying Erdheim-Chester disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there are other involved sites such as the pancreas or mesentery. In these cases, pancreatic cancer, IgG4-related or unrelated chronic pancreatitis, or sclerosing mesenteritis should be suspected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If local expertise with radiologic diagnosis of RPF is limited.
        </p>
        <p>
        </p>
        <p>
         A biopsy may be performed either with CT-guidance or as an open (surgical) procedure [
         <a href="#rid18">
          18,44,47
         </a>
         ]. Sometimes, an open biopsy is needed if the tissue obtained by CT-guidance yields inconclusive results. An open biopsy may also be performed as part of a surgical procedure planned for relief of urinary obstruction or correction of an abdominal aortic aneurysm. For the lowest risk of complications and the optimal diagnostic yield, the biopsy specimen should be obtained where the tissue is thickest and in areas that were demonstrated to be hypermetabolic on PET (if a PET scan was performed).
        </p>
        <p>
         The pathologic findings of idiopathic and secondary disease may sometimes be indistinguishable [
         <a href="#rid1">
          1
         </a>
         ]. Macroscopically, RPF appears as a hard white plaque of varying thickness surrounding the abdominal aorta, iliac vessels, inferior vena cava, and the ureters. Microscopically, the tissue comprises an extracellular matrix composed of type I collagen fibers organized in thick irregular bundles that surround small retroperitoneal vessels. The fibrous tissue is also rich in fibroblasts or myofibroblasts [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Inflammatory infiltrate consisting of B and T lymphocytes, macrophages, plasma cells, and, rarely, neutrophils may be present in a diffuse, pseudo-nodular, or perivascular aggregate configuration. The aggregates usually have a core rich in cluster of differentiation 20 (CD20) positive B cells and a periphery rich in CD3 positive T cells, with a CD4-to-CD8 ratio of 3:1. A varying percentage of immunoglobulin G4 (IgG4) positive plasma cells can be observed. If the proportion of CD138-positive plasma cells that are IgG4 positive is greater than 30 to 40 percent, then the RPF is likely IgG4-related. IgG4-related disease accounts for up to 50 percent of RPF cases [
         <a href="#rid55">
          55,56
         </a>
         ]. However, the absence of IgG4-positive plasma cells does not necessarily rule out IgG4-related disease, as other extra-retroperitoneal IgG4-positive lesions may appear. Storiform fibrosis and obliterative phlebitis are also consistent with IgG4-related RPF.
        </p>
        <p>
         Additional histologic features of idiopathic RPF include vasculitis of small retroperitoneal vessels (noted in approximately one-half of the cases) and hyaline rinds surrounding small retroperitoneal vessels and nerves.
        </p>
        <p>
         Secondary forms of RPF due to malignancies are characterized by the presence of neoplastic cells scattered among an abundant fibrous tissue; the inflammatory infiltrate can be monoclonal in cases of lymphoma. In Erdheim-Chester disease, the presence of "foamy" histiocytes (CD68KP1 positive, CD1a negative) is a hallmark of the histologic pattern. Granulomatous formations are unusual in idiopathic RPF and should raise suspicion for tuberculosis or other granulomatous conditions.
        </p>
        <p class="headingAnchor" id="H1934619689">
         <span class="h2">
          Distinguishing between primary and secondary disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once a diagnosis of RPF is made, it is important to distinguish whether the patient has idiopathic or secondary disease. This is primarily to guide next steps in the evaluation, monitoring, and treatment of RPF. (See
         <a class="medical medical_review" href="/z/d/html/7213.html" rel="external">
          "Treatment of retroperitoneal fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H618184047">
         <span class="h3">
          Features suggestive of idiopathic (primary) disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main features suggestive of idiopathic RPF are its appearance on CT or MRI and the absence of clinical and laboratory signs of infection (eg, persistent high-grade fever, leukocytosis) or malignancy (eg, marked weight loss, gastrointestinal bleeding, or metastatic lesions on CT, MRI, or PET).
        </p>
        <p>
         However, as noted above, some forms of secondary RPF may be radiographically and histologically indistinguishable from idiopathic RPF. (See
         <a class="local">
          'Diagnosis (contrast CT or MRI preferred)'
         </a>
         above and
         <a class="local">
          'Indications for a biopsy and diagnostic histopathology'
         </a>
         above.)
        </p>
        <p>
         In such cases, the history, examination, and laboratory evaluation may suggest the presence of a secondary cause. (See
         <a class="local">
          'Features suggestive of secondary disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H702753895">
         <span class="h3">
          Features suggestive of secondary disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients who have a radiologic diagnosis of RPF, causes of secondary RPF should be sought. (See
         <a class="local">
          'Etiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
         The patient should be asked about a history of the following to identify any potential cause of secondary disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs – Prolonged use of ergot-derivatives, methysergide,
         <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">
          bromocriptine
         </a>
         , beta blockers,
         <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">
          methyldopa
         </a>
         ,
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         , and analgesics. Some drugs (ie, ergot-derivatives and dopamine agonists) have clearly causal associations with RPF; in such cases, further evaluation for other secondary causes is generally not performed [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biological agents such as
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , a soluble receptor that acts as a tumor necrosis factor (TNF)-alpha blocker, and
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         , an anti-TNF-alpha monoclonal antibody.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancy – Carcinoid, Hodgkin and non-Hodgkin lymphoma, sarcomas, colorectal, breast, prostate, and bladder carcinoma  (
         <a class="graphic graphic_diagnosticimage graphicRef93886" href="/z/d/graphic/93886.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef93885" href="/z/d/graphic/93885.html" rel="external">
          image 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infections – Tuberculosis, histoplasmosis, actinomycosis. Actinomycosis should be ruled out in women with a history of intrauterine device use. (See
         <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">
          "Intrauterine contraception: Management of side effects and complications", section on 'Actinomyces and related organisms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation therapy for testicular seminoma, colon, pancreatic cancer  (
         <a class="graphic graphic_diagnosticimage graphicRef93887" href="/z/d/graphic/93887.html" rel="external">
          image 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retroperitoneal hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgery – Lymphadenectomy, colectomy, aortic aneurysmectomy.
        </p>
        <p>
        </p>
        <p>
         In addition to the history, a CT or MRI may reveal secondary causes, such as malignancies (lymphoma, carcinoid, or retroperitoneal sarcomas), or infection (tuberculosis, histoplasmosis, or actinomycosis). PET has a low specificity for distinguishing between idiopathic and secondary disease [
         <a href="#rid58">
          58-60
         </a>
         ]. Further evaluation of patients with radiographic features suggestive of such secondary conditions is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4696.html" rel="external">
          "Pretreatment evaluation and staging of non-Hodgkin lymphomas", section on 'Imaging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">
          "Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Imaging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">
          "Diagnosis of carcinoid syndrome and tumor localization", section on 'Tumor localization and staging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults", section on 'Radiographic imaging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2691.html" rel="external">
          "Abdominal actinomycosis", section on 'Radiologic findings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2461.html" rel="external">
          "Diagnosis and treatment of disseminated histoplasmosis in patients without HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7736.html" rel="external">
          "Clinical presentation and diagnosis of retroperitoneal soft tissue sarcoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2996208628">
         <span class="h2">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients have already had routine laboratory testing by the time they are diagnosed with RPF (ie, complete blood count, electrolytes, creatinine, liver function tests). There are no hematologic or biochemical abnormalities that are specific to RPF.
        </p>
        <p>
         We order the following additional tests, which may help determine the underlying etiology of RPF:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), which are typically elevated at the time of diagnosis and may be helpful in monitoring the response to therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum immunoglobulin levels including IgG4.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid function tests.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoantibodies such as antinuclear antibody, anti-thyroid microsome, anti-thyroglobulin, anti-neutrophil cytoplasmic antibody, or anti-smooth muscle antibodies. Antibody tests may be omitted among patients with an unequivocal diagnosis of secondary RPF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum protein electrophoresis and serum free light chain assay.
        </p>
        <p>
        </p>
        <p>
         Patients often have normocytic anemia possibly related to chronic kidney disease or chronic inflammation [
         <a href="#rid1">
          1,5,11,61,62
         </a>
         ]. Other less common abnormalities include leukocytosis and eosinophilia.
        </p>
        <p>
         ESR and CRP are elevated in a majority of patients at presentation, reflecting the inflammatory nature of the disease [
         <a href="#rid5">
          5,63
         </a>
         ]. As an example, in one study of 53 patients with RPF, 74 and 62 percent had an elevated ESR and CRP, respectively [
         <a href="#rid5">
          5
         </a>
         ]. High baseline levels of acute phase reactants are associated with more symptomatic disease, but levels generally do not correlate with the risk of subsequent disease flares.
        </p>
        <p>
         Antinuclear antibody (ANA) may be present in up to 60 percent of cases of idiopathic RPF and may also predict relapse after therapy [
         <a href="#rid64">
          64-66
         </a>
         ]. Other autoantibodies usually suggest the presence of concomitant autoimmune disease. As an example, about 25 percent of patients with idiopathic RPF have autoimmune thyroiditis, and such patients will have antibodies against thyroid microsome and thyroglobulin [
         <a href="#rid57">
          57
         </a>
         ]. A positive antineutrophil cytoplasmic antibody (ANCA) may be present in patients who have granulomatosis with polyangiitis and microscopic polyangiitis in conjunction with RPF.
        </p>
        <p>
         Patients with RPF may have a nonspecific elevation of serum IgG4 [
         <a href="#rid55">
          55
         </a>
         ]. Compared with patients without elevated IgG4, patients with elevated IgG4 levels have more frequent fibroinflammatory lesions outside the retroperitoneum, but otherwise do not differ in their demographic, laboratory, or clinical presentation. However, IgG4 levels may also be elevated in other inflammatory or proliferative diseases that can mimic RPF, such as Castleman disease and Erdheim-Chester disease. (See
         <a class="medical medical_review" href="/z/d/html/90340.html" rel="external">
          "Unicentric Castleman disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117312.html" rel="external">
          "HHV-8-negative/idiopathic multicentric Castleman disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4707.html" rel="external">
          "HHV-8/KSHV-associated multicentric Castleman disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13942.html" rel="external">
          "Erdheim-Chester disease"
         </a>
         .)
        </p>
        <p>
         Monoclonal or polyclonal dysproteinemias associated with RPF have also been reported. In one such report, all five affected patients had immunoglobulin heavy chain gene rearrangement [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients present with abdominal or flank pain and kidney function impairment. Among such patients, the major differential diagnosis prior to imaging is nephrolithiasis, which is excluded by computed tomography (CT) scan. Among patients who have findings of hydronephrosis associated with presence of abnormal findings in the retroperitoneum, the differential diagnosis includes other conditions, including [
         <a href="#rid68">
          68,69
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoma, germ cell tumors, or sarcomas of retroperitoneal origin (see
         <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">
          "Clinical presentation and initial evaluation of non-Hodgkin lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7736.html" rel="external">
          "Clinical presentation and diagnosis of retroperitoneal soft tissue sarcoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2998.html" rel="external">
          "Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retroperitoneal metastases from various types of carcinomas (eg, carcinoma of the prostate, breast, colon) with an exuberant desmoplastic response (see
         <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">
          "Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">
          "Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/767.html" rel="external">
          "Overview of the approach to metastatic breast cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retroperitoneal fibromatosis (see
         <a class="medical medical_review" href="/z/d/html/7746.html" rel="external">
          "Desmoid tumors: Epidemiology, molecular pathogenesis, clinical presentation, diagnosis, and local therapy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammatory pseudotumor (see
         <a class="medical medical_review" href="/z/d/html/4352.html" rel="external">
          "Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infections such as tuberculosis and actinomycosis; actinomycosis should be ruled out in women with a history of intrauterine device use (see
         <a class="medical medical_review" href="/z/d/html/7026.html" rel="external">
          "Pulmonary tuberculosis: Clinical manifestations and complications", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">
          "Intrauterine contraception: Management of side effects and complications", section on 'Actinomyces and related organisms'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erdheim-Chester disease (see
         <a class="medical medical_review" href="/z/d/html/13942.html" rel="external">
          "Erdheim-Chester disease", section on 'Clinical manifestations'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         As described above, certain characteristics on CT or magnetic resonance imaging scan may distinguish RPF from other retroperitoneal lesions. The presence of a confluent lymphadenopathy that tends to surround the large vessels is likely to be malignant, as is a fibrous mass dislocating the psoas muscles or destroying bone [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="local">
          'Diagnosis (contrast CT or MRI preferred)'
         </a>
         above.)
        </p>
        <p>
         Erdheim-Chester disease should be suspected in cases of symmetrical and bilateral perirenal fibrosis [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         When the thoracic aorta and/or the epiaortic arteries are involved, giant-cell arteritis and Takayasu arteritis should be excluded.
        </p>
        <p class="headingAnchor" id="H3863917522">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">
          "Society guideline links: Chronic kidney disease in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/117964.html" rel="external">
          "Society guideline links: IgG4-related disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retroperitoneal fibrosis (RPF) is a rare condition characterized by the presence of inflammatory and fibrous tissue in the retroperitoneum. The tissue is generally localized around the infrarenal portion of the abdominal aorta and the iliac arteries, often encasing the ureters or other abdominal organs. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RPF may be idiopathic or secondary to other causes. Idiopathic RPF is an immune-mediated disease that can either present in isolation or in association with other autoimmune diseases, such as the fibroinflammatory immunoglobulin G4 (IgG4)-related disease. Idiopathic RPF (in its typical periaortic presentation) probably arises as an aortitis and elicits a periaortic fibroinflammatory response. Secondary RPF can be caused by a number of factors, including drugs, malignancy, infections, radiation therapy, retroperitoneal hemorrhage, and surgery. (See
         <a class="local">
          'Etiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Typically, patients with RPF present with pain in the lower back, abdomen, or flank. Estimated glomerular filtration rate (eGFR) is often decreased at the time of presentation, usually as a result of urinary tract obstruction. Other common symptoms, which may occur with pain or in isolation, include malaise, anorexia, weight loss, fever, nausea, vomiting, and lower extremity edema. Edema may be due to inferior vena cava or lymphatic compression. Other findings can include new-onset hypertension and, in men, hydrocele or varicocele. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of RPF is often made either by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis without and with contrast. MRI is equivalent to CT in the diagnosis of RPF. The use of gadolinium is recommended in order to define the exact extension of the tissue and to study the vasculature; however, if gadolinium cannot be used, unenhanced MRI can still differentiate RPF from the surrounding tissues. (See
         <a class="local">
          'Diagnosis (contrast CT or MRI preferred)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Typical findings of idiopathic RPF include presence of a confluent retroperitoneal mass, with homogeneous attenuation similar to muscle, that encases (but not displaces) the anterior and lateral sides of the aorta, encircles and compresses the inferior vena cava, and often causes a medial deviation of the ureters  (
         <a class="graphic graphic_diagnosticimage graphicRef55419" href="/z/d/graphic/55419.html" rel="external">
          image 5
         </a>
         ). In addition to revealing the presence of RPF, cross-sectional imaging can sometimes suggest a secondary cause of RPF (eg, malignancy, prior surgery, prior radiotherapy). By contrast, other causes of secondary RPF may be radiographically indistinguishable from idiopathic RPF (eg, drug-induced RPF). (See
         <a class="local">
          'Diagnosis (contrast CT or MRI preferred)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Many clinicians do not perform a biopsy in patients who have an imaging diagnosis of idiopathic RPF, unless the patient is about to undergo surgery for repair of abdominal aortic aneurysm (in the case of inflammatory aneurysms or perianeurysmal fibrosis) or for surgical ureterolysis to treat urinary tract obstruction. We suggest a biopsy in the following settings (see
         <a class="local">
          'Indications for a biopsy and diagnostic histopathology'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the location of the mass is atypical (eg, not periaortoiliac but instead in a pelvic, isolated periureteral, or peribladder location).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If clinical and laboratory findings suggest the presence of an underlying malignancy or infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If there is bulky appearance of the retroperitoneal tissue, extension above the origin of the renal arteries, anterior displacement of the aorta, or infiltration of muscles, bone, or other structures and confluent lymphadenopathy. This appearance suggests the possibility of an underlying malignancy (eg, lymphoma, sarcoma, or other solid neoplasms).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If there is a perirenal fibrotic tissue. This appearance suggests the possibility of underlying Erdheim-Chester disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If there are other involved sites such as the pancreas or mesentery. In these cases, pancreatic cancer, IgG4-related or unrelated chronic pancreatitis, or sclerosing mesenteritis should be suspected.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If local expertise with radiologic diagnosis of RPF is limited.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The main features suggestive of idiopathic RPF are its appearance on CT or MRI and the absence of clinical and laboratory signs of infection (eg, persistent high-grade fever, leukocytosis) or malignancy (eg, marked weight loss, gastrointestinal bleeding, or metastatic lesions on CT, MRI, or positron emission tomography). However, some forms of secondary RPF may be radiographically and histologically indistinguishable from idiopathic RPF. In such cases, the history, examination, and laboratory evaluation may suggest the presence of a secondary cause. (See
         <a class="local">
          'Features suggestive of idiopathic (primary) disease'
         </a>
         above and
         <a class="local">
          'Features suggestive of secondary disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H346556538">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Carlo Buzio, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006; 367:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ORMOND JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol 1948; 59:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Curr Rheumatol Rep 2021; 23:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uibu T, Oksa P, Auvinen A, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet 2004; 363:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 2009; 88:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaglio A. Retroperitoneal fibrosis: new insights into clinical presentation and diagnosis. Medicine (Baltimore) 2009; 88:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen TE, Hallett JW Jr. Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis. Ann Surg 1997; 225:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koep L, Zuidema GD. The clinical significance of retroperitoneal fibrosis. Surgery 1977; 81:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasales CJ, Hartman DS. Genitourinary case of the day. Retroperitoneal fibrosis. AJR Am J Roentgenol 1994; 162:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011; 378:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore) 2009; 88:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmisano A, Urban ML, Corradi D, et al. Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? Rheumatology (Oxford) 2015; 54:2004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldoni M, Bonini S, Urban ML, et al. Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study. Ann Intern Med 2014; 161:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nesti M, Marinaccio A, Chellini E. Malignant mesothelioma in Italy, 1997. Am J Ind Med 2004; 45:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronin CG, Lohan DG, Blake MA, et al. Retroperitoneal fibrosis: a review of clinical features and imaging findings. AJR Am J Roentgenol 2008; 191:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang K, Wang Z, Zeng Q, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One 2021; 16:e0245601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi GM, Rocco R, Accorsi Buttini E, et al. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med 2017; 12:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Bommel EF. Retroperitoneal fibrosis. Neth J Med 2002; 60:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmisano A, Maritati F, Vaglio A. Chronic Periaortitis: an Update. Curr Rheumatol Rep 2018; 20:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Calamia KT, Matteson EL, et al. Vasculitis of the gastrointestinal tract in chronic periaortitis. Medicine (Baltimore) 2011; 90:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamano H, Kawa S, Ochi Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet 2002; 359:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martorana D, Márquez A, Carmona FD, et al. A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. J Allergy Clin Immunol 2018; 142:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramshaw AL, Roskell DE, Parums DV. Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis). J Clin Pathol 1994; 47:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangieri D, Corradi D, Martorana D, et al. Eotaxin/CCL11 in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant 2012; 27:3875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaglio A, Catanoso MG, Spaggiari L, et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum 2013; 65:2469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicastro M, Vescovini R, Maritati F, et al. Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis. Arthritis Rheumatol 2019; 71:1913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966; 274:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           UTZ DC, ROOKE ED, SPITTELL JA Jr, BARTHOLOMEW LG. RETROPERITONEAL FIBROSIS IN PATIENTS TAKING METHYSERGIDE. JAMA 1965; 191:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goenka AH, Shah SN, Remer EM. Imaging of the retroperitoneum. Radiol Clin North Am 2012; 50:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couderc M, Mathieu S, Dubost JJ, Soubrier M. Retroperitoneal fibrosis during etanercept therapy for rheumatoid arthritis. J Rheumatol 2013; 40:1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosaka N, Ito M, Taki Y, et al. Amyloid A gastrointestinal amyloidosis associated with idiopathic retroperitoneal fibrosis. Report of a rare autopsy case and review of the literature. Arch Pathol Lab Med 2003; 127:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jendro MC, Zeidler H, Rosenthal H, et al. Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. Clin Rheumatol 2004; 23:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janssen T, van Cangh PJ. [Retroperitoneal fibrosis due to barium]. Prog Urol 1994; 4:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remmele W, Müller-Lobeck H, Paulus W. Primary mesenteritis, mesenteric fibrosis and mesenteric fibromatosis. Report of four cases, pathology, and classification. Pathol Res Pract 1988; 184:77.
          </a>
         </li>
         <li class="breakAll">
          Witten DM. Retroperitoneal fibrosis. In: Clinical Urography, Pollack HM (Ed), WB Saunders, Philadelphia 1990. p.2469.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demko TM, Diamond JR, Groff J. Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations. J Am Soc Nephrol 1997; 8:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Littlejohn GO, Keystone EC. The association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of the literature. J Rheumatol 1981; 8:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           QUE GS, MANDEMA E. A CASE OF IDIOPATHIC RETROPERITONEAL FIBROSIS PRESENTING AS A SYSTEMIC COLLAGEN DISEASE. Am J Med 1964; 36:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxton HM, Kilpatrick FR, Kinder CH, et al. Retroperitoneal fibrosis. A radiological and follow-up study of fourteen cases. Q J Med 1969; 38:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmisano A, Cobelli R, Buzio C, Vaglio A. Peri-renal collateral circles. Urology 2009; 74:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant 2021; 36:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feinstein RS, Gatewood OM, Goldman SM, et al. Computerized tomography in the diagnosis of retroperitoneal fibrosis. J Urol 1981; 126:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jois RN, Gaffney K, Marshall T, Scott DG. Chronic periaortitis. Rheumatology (Oxford) 2004; 43:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalla-Palma L, Rocca-Rossetti S, Pozzi-Mucelli RS, Rizzatto G. Computed tomography in the diagnosis of retroperitoneal fibrosis. Urol Radiol 1981; 3:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George V, Tammisetti VS, Surabhi VR, Shanbhogue AK. Chronic fibrosing conditions in abdominal imaging. Radiographics 2013; 33:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amis ES Jr. Retroperitoneal fibrosis. AJR Am J Roentgenol 1991; 157:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arrivé L, Hricak H, Tavares NJ, Miller TR. Malignant versus nonmalignant retroperitoneal fibrosis: differentiation with MR imaging. Radiology 1989; 172:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakir B, Yilmaz F, Turkay R, et al. Role of diffusion-weighted MR imaging in the differentiation of benign retroperitoneal fibrosis from malignant neoplasm: preliminary study. Radiology 2014; 272:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohan RH, Shampain KL, Francis IR, et al. Imaging appearance of fibrosing diseases of the retroperitoneum: can a definitive diagnosis be made? Abdom Radiol (NY) 2018; 43:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moroni G, Castellani M, Balzani A, et al. The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 2012; 39:1635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Persky L, Huus JC. Atypical manifestations of retroperitoneal fibrosis. J Urol 1974; 111:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saldino RM, Palubinskas AJ. Medial placement of the ureter: a normal variant which may simulate retroperitoneal fibrosis. J Urol 1972; 107:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corradi D, Maestri R, Palmisano A, et al. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int 2007; 72:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maritati F, Rocco R, Accorsi Buttini E, et al. Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients. Front Immunol 2019; 10:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zen Y, Inoue D, Kitao A, et al. IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases. Am J Surg Pathol 2009; 33:1886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceresini G, Urban ML, Corradi D, et al. Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: a case-control study. Autoimmun Rev 2015; 14:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fendler WP, Eiber M, Stief CG, Herrmann K. A PET for All Seasons: 18F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis? Eur Urol 2017; 71:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernando A, Pattison J, Horsfield C, et al. [18F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. Eur Urol 2017; 71:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Accorsi Buttini E, Maritati F, Vaglio A. [18F]-Fluorodeoxyglucose Positron Emission Tomography and Response to Therapy in Idiopathic Retroperitoneal Fibrosis. Eur Urol 2018; 73:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker LR, Mallinson WJ, Gregory MC, et al. Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol 1987; 60:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warnatz K, Keskin AG, Uhl M, et al. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005; 64:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magrey MN, Husni ME, Kushner I, Calabrese LH. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum 2009; 61:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaglio A, Corradi D, Manenti L, et al. Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med 2003; 114:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raffiotta F, da Silva Escoli R, Quaglini S, et al. Idiopathic Retroperitoneal Fibrosis: Long-term Risk and Predictors of Relapse. Am J Kidney Dis 2019; 74:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moriconi D, Giannese D, Capecchi R, et al. Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis. Clin Exp Nephrol 2019; 23:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oshiro H, Ebihara Y, Serizawa H, et al. Idiopathic retroperitoneal fibrosis associated with immunohematological abnormalities. Am J Med 2005; 118:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emley TE, Cain MP, Faught PR, Davis MM. Ureteropelvic junction obstruction due to inflammatory pseudotumor masquerading as hydronephrosis because of a neuropathic bladder in a child with myelomeningocele. Urology 2001; 58:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoeckle E, Coindre JM, Bonvalot S, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 2001; 92:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mirault T, Lambert M, Puech P, et al. Malignant retroperitoneal fibrosis: MRI characteristics in 50 patients. Medicine (Baltimore) 2012; 91:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmisano A, Vaglio A. Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res Clin Rheumatol 2009; 23:339.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7200 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16427494" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18858051" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33569638" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15121404" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Asbestos exposure as a risk factor for retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19593223" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19593225" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Retroperitoneal fibrosis: new insights into clinical presentation and diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9065292" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/841463" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The clinical significance of retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8192023" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Genitourinary case of the day. Retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21733570" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19593224" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26106209" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25089862" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14691969" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Malignant mesothelioma in Italy, 1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18647912" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Retroperitoneal fibrosis: a review of clinical features and imaging findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33600452" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28070877" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12365466" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30397845" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Chronic Periaortitis: an Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21200184" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Vasculitis of the gastrointestinal tract in chronic periaortitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11978339" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30081155" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962625" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17518371" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23114905" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Eotaxin/CCL11 in idiopathic retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23740665" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31233292" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5903120" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Fibrotic disorders associated with methysergide therapy for headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14257741" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : RETROPERITONEAL FIBROSIS IN PATIENTS TAKING METHYSERGIDE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22498446" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Imaging of the retroperitoneum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24187163" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Retroperitoneal fibrosis during etanercept therapy for rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12741901" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Amyloid A gastrointestinal amyloidosis associated with idiopathic retroperitoneal fibrosis. Report of a rare autopsy case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14749985" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8044188" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : [Retroperitoneal fibrosis due to barium].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3231572" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Primary mesenteritis, mesenteric fibrosis and mesenteric fibromatosis. Report of four cases, pathology, and classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3231572" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Primary mesenteritis, mesenteric fibrosis and mesenteric fibromatosis. Report of four cases, pathology, and classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10495799" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6975379" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14124699" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A CASE OF IDIOPATHIC RETROPERITONEAL FIBROSIS PRESENTING AS A SYSTEMIC COLLAGEN DISEASE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5769557" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Retroperitoneal fibrosis. A radiological and follow-up study of fourteen cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19476982" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Peri-renal collateral circles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33005943" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Idiopathic retroperitoneal fibrosis: an update for nephrologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7265376" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Computerized tomography in the diagnosis of retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15266064" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Chronic periaortitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7314324" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Computed tomography in the diagnosis of retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23842972" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Chronic fibrosing conditions in abdominal imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1853816" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2740497" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Malignant versus nonmalignant retroperitoneal fibrosis: differentiation with MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24702726" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Role of diffusion-weighted MR imaging in the differentiation of benign retroperitoneal fibrosis from malignant neoplasm: preliminary study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28849414" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Imaging appearance of fibrosing diseases of the retroperitoneum: can a definitive diagnosis be made?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22801728" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4813573" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Atypical manifestations of retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5014361" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Medial placement of the ureter: a normal variant which may simulate retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17622270" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31019511" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19898222" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25172237" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28111114" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A PET for All Seasons: 18F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27876167" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : [18F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29033102" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : [18F]-Fluorodeoxyglucose Positron Emission Tomography and Response to Therapy in Idiopathic Retroperitoneal Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3427331" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15897305" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19404998" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12727578" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Evidence of autoimmunity in chronic periaortitis: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31204195" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Idiopathic Retroperitoneal Fibrosis: Long-term Risk and Predictors of Relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31230189" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15989914" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Idiopathic retroperitoneal fibrosis associated with immunohematological abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11445491" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Ureteropelvic junction obstruction due to inflammatory pseudotumor masquerading as hydronephrosis because of a neuropathic bladder in a child with myelomeningocele.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11466691" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22932788" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Malignant retroperitoneal fibrosis: MRI characteristics in 50 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508942" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Chronic periaortitis: a fibro-inflammatory disorder.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
